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Letters
RESEARCH LETTER

Bridging Anticoagulation Before Colonoscopy:
Results of a Multispecialty Clinician Survey
Long-term anticoagulant therapy is essential for stroke prevention among patients with atrial fibrillation, but increasing
evidence also points to substantial risk for adverse events, especially when anticoagulation is temporarily interrupted.1,2 The
recently published Effectiveness of Bridging Anticoagulation
for Surgery Trial confirmed prior observational evidence that
using short-acting anticoagulants periprocedurally increases
bleeding risk without any reduction in stroke risk.3 Little is
known about how medical specialists coordinate the complex decision of which patients to bridge. To investigate this
question, we conducted a regional multispecialty, multicenter survey study regarding bridging practices.
Methods | Between July 29, 2015, and September 8, 2015, we
surveyed all primary care physicians (PCPs), cardiologists, and
gastroenterologists at the University of Michigan (primary site)
and 4 other health care centers (secondary sites) participating in the Blue Cross Blue Shield of Michigan–sponsored Michigan Anticoagulation Quality Improvement Initiative.2 Participants were excluded if they reported no involvement in patient
care or bridging decisions. Clinicians were presented with 4
hypothetical vignettes of patients with atrial fibrillation who
must temporarily discontinue warfarin for an upcoming colonoscopy (Table). The vignettes varied in number of stroke risk
factors and were presented in random order to each partici-

pant to minimize assimilation effect bias.4 Clinicians were
asked to indicate whether they would recommend bridging
with low-molecular-weight heparin for each vignette. Clinicians were also asked about their current experience with periprocedural anticoagulation management, as well as who should
be responsible for anticoagulation bridging decisions. Multivariable logistic regression models and Wald tests were used
to assess adjusted response rate differences between clinician specialties. This study was deemed exempt by the institutional review board at the University of Michigan; consent
was implied through participation in the optional survey.
Results | A total of 127 of 262 clinicians (48.5%) at the primary
site and 80 of 496 clinicians (16.1%) at the secondary sites completed the survey. Respondents were well distributed across
medical specialties and reported high levels of participation
in bridging anticoagulation management (72.5% reported at
least once per month). For intermediate-risk patients (CHADS2
[congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke or transient ischemic attack] score = 3), there
was significant variation in the recommendation to use bridging anticoagulation among specialties (Table). Notably, all specialties were more likely to recommend bridging for a patient
with a CHADS2 score of 3 if the patient had a prior ischemic
stroke compared with a patient with equal risk but no prior
ischemic stroke (73.9% vs 37.2%; P < .001).
There was wide consensus across specialties that a nongastroenterologist should be responsible for making bridging
decisions (197 of 207; 95.2%), with large numbers of respon-

Table. Survey Vignettes and Responsesa

Vignette
A 66-y-old man with AF
and hypertension

Use of Bridging Anticoagulation, No. (%)

Stroke Risk
Elements

Prior
Ischemic
Stroke

Site

All Respondents
(N = 207)

Gastroenterology
(n = 32 [15.5%])

CHADS2 = 1

No

Primary

7 (5.5)

1 (2.9)

5 (7.6)

No

Secondary

5 (6.3)

0 (0)

4 (7.3)

CHADS2 = 3

No

Primary

45 (35.4)

7 (20.0)

28 (42.4)b

CHA2DS2-VASc = 4

No

Secondary

32 (40.0)

4 (21.1)

26 (47.3)b

1 (16.7)

A 66-y-old man with AF,
hypertension, and a prior
ischemic stroke

CHADS2 = 3

Yes

Primary

98 (77.2)

21 (60.0)

53 (80.3)b

21 (80.8)b

CHA2DS2-VASc = 4

Yes

Secondary

55 (68.8)

10 (52.6)

42 (76.4)b

3 (50.0)

A 66-y-old man with AF,
hypertension, diabetes,
congestive HF, and
a prior ischemic stroke

CHADS2 = 5

Yes

Primary

111 (87.4)

27 (77.1)

60 (90.9)

24 (92.3)b

CHA2DS2-VASc = 6

Yes

Secondary

70 (87.5)

15 (78.9)

51 (93.0)

5 (83.3)

All vignettes describe a warfarin-treated patient with AF who requires
temporary interruption for an upcoming colonoscopy. Survey respondents are

2 (7.7)
0 (0)
11 (42.3)b

asked to report when use of bridging with a short-acting anticoagulant (either
heparin or low-molecular-weight heparin) would be recommended. Primary
care physicians represent 52.0% and 68.8% of respondents at the primary
and secondary sites, respectively. Presented survey responses are adjusted for
clinician specialty, year of medical school graduation, self-reported mean
number of patients seen per week, and self-reported mean number of
periprocedural anticoagulation decisions made per month.

Abbreviations: AF, atrial fibrillation; CHADS2, congestive heart failure,
hypertension, age ⱖ75 years, diabetes, prior stroke or transient ischemic
attack; CHA2DS2-VASc, congestive heart failure, hypertension, age ⱖ75 years
(doubled), diabetes, stroke/transient ischemic attack/thromboembolism
(doubled), vascular disease (prior myocardial infarction, peripheral artery
disease, or aortic plaque), age 65 to 75 years, sex category (female); HF, heart
failure; PCP, primary care physician.
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PCP
(n = 121 [58.5%])

CHA2DS2-VASc = 2

A 66-y-old man with AF,
hypertension, diabetes,
and congestive HF

a

Cardiology
(n = 54 [26.1%])

b

P < .05 as compared with cardiology.
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dents believing that PCPs (51 of 207; 24.6%) or cardiologists
(100 of 207; 48.3%) should be responsible. Notably, 32.2% of
PCPs (39 of 121) felt uncomfortable managing periprocedural
anticoagulation. Among PCPs, 81.8% (99 of 121) indicated that
their institutions could do more to support perioperative anticoagulation and 87.6% (106 of 121) supported anticoagulation clinic management of this clinical situation.
Discussion | A high proportion of clinicians who frequently
manage periprocedural anticoagulation continue to recommend bridging anticoagulation for intermediate-risk patients
despite the recent publication of a high-quality randomized
trial demonstrating net harm from this practice. Furthermore, there is little consensus about whether PCPs or cardiologists should be responsible for making the complex decision of whether to bridge or not. Our data suggest that this is
especially important because the 2 groups have significantly
different approaches to bridging, and a substantial proportion of PCPs reported being uncomfortable making bridging
decisions. Prior work has highlighted use of bridging anticoagulation for up to 25% of warfarin-treated patients undergoing colonoscopy.5,6
The results were consistent across a range of medical centers (academic and nonacademic). The generalizability of these
findings, while limited by the few sites surveyed and the low
response rate at the secondary sites, is bolstered by the potential bias for more informed clinicians to respond to a survey about anticoagulation management, for which they routinely make clinical decisions.
These results should encourage robust implementation
efforts to standardize periprocedural anticoagulation management. Because periprocedural bridging is by nature complex and multidisciplinary, clinical leaders and policy makers need to assess the readiness of different specialists and
support anticoagulation clinics to manage periprocedural
anticoagulation.
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A Quality Improvement Program for Recognition
and Treatment of Inpatient ST-Segment Elevation
Myocardial Infarctions
Rapid reperfusion with percutaneous coronary intervention
or thrombolytic therapy is the standard of care for STsegment elevation myocardial infarction (STEMI). STEMIs that
occur in hospitalized patients have delayed symptom recognition, longer times from electrocardiography (ECG) to firstdevice activation (FDA), lower rates of percutaneous coronary intervention, and higher mortality rates compared with
outpatient STEMIs.1-6
We identified the barriers contributing to these delays and
implemented a quality improvement program (QIP) to enhance the response to inpatient STEMIs. Our QIP included the
following 4 specific interventions: (1) a hospital-wide education campaign aimed at nurses, medical teams, and allied health
care professionals on the recognition of inpatient STEMI and the
importance of the timely reperfusion; (2) a requirement that ECG
technicians and nurses immediately notify the cardiologist if
the automated interpretation of an ECG included ***acute MI***;
(3) establishment of an inpatient STEMI protocol and a cardiac
response team, modeled on the rapid response team; and
(4) monthly review of each inpatient STEMI.
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